What is ibogaine, and why is it in the news?

This episode of Science Friday explores the rising public interest in ibogaine, a psychedelic compound derived from the root bark of the iboga plant in Central Africa. Once a niche topic among underground addiction treatment circles, ibogaine has recently gained national attention after being endorsed by Joe Rogan and supported by President Trump’s administration, which announced plans to fast-track psychedelic therapy research and loosen FDA regulations. Neuroscientist Dr. Debra Mash, a pioneer in ibogaine research since the 1990s, shares her firsthand experiences observing its transformative effects on addicts in Amsterdam, where patients reported not only withdrawal relief but profound psychological shifts and emotional healing. Despite its potential, ibogaine remains controversial due to serious cardiac risks, particularly its effect on the HERG potassium channel, which can lead to fatal arrhythmias. The episode also highlights the development of noribogaine, a safer metabolite of ibogaine that lacks hallucinogenic properties, now approved for clinical testing by the FDA. Journalist Jane Hu adds context on the cultural and social drivers behind ibogaine’s resurgence, including veteran-led advocacy and retreat communities in Mexico. The discussion underscores a growing demand for alternative treatments for addiction and PTSD, especially as traditional therapies have failed many patients.